Antitumor Cytisine-Platinum Prodrug CP12 Experimental Data

Experimental results for the antitumor compound CP12, a cytisine-platinum(IV) prodrug. It was generated by author Ruo-Xi Sang to study mechanisms of immunogenic cell death in lung cancer. The dataset is published under a CC BY-NC 4.0 license and was last updated in March 2026.

Use Cases

• Analyze CP12-induced ER stress and mitochondrial calcium overload data to model the IP3R1-GRP75-VDAC1 axis.
• Correlate CP12 treatment levels with measurements of mitochondrial membrane potential collapse and reactive oxygen species bursts.
• Model the relationship between CP12's dual DNA damage and activation metrics for the cGAS-STING pathway.
• Evaluate CP12's in vivo efficacy data against lung cancer growth and its hepatorenal toxicity profile compared to cisplatin.

Strengths

• Data is focused on a specific, highly active compound (CP12) with demonstrated antitumor activity.
• Dataset covers multiple mechanistic aspects: chemical damage, organelle dysfunction, and immune activation.
• Findings are validated in an in vivo lung cancer model, providing translational relevance.

Limitations

• The dataset is extremely small, with a file size of only 986.0 B, indicating very limited data points.
• Specific column names, row counts, and sample data are unavailable, hindering assessment of structure and scope.
• Data is derived from a single study on one compound (CP12), limiting generalizability to other agents.

Provenance

Source

Ruo-Xi Sang via figshare.

Collection Method

Data generated from the design, synthesis, and experimental testing of Pt(IV) prodrug derivatives.

Freshness

Last updated in March 2026.